James M Fisher1, Nils Y Hammerla2, Thomas Ploetz2, Peter Andras3, Lynn Rochester4, Richard W Walker5. 1. Department of Medicine, Northumbria Healthcare NHS Foundation Trust, United Kingdom. Electronic address: drjamesfisher@hotmail.com. 2. School of Computing Science, Newcastle University, United Kingdom. 3. School of Computing and Mathematics, Keele University, United Kingdom. 4. Institute for Ageing and Health, Newcastle University, United Kingdom. 5. Department of Medicine, Northumbria Healthcare NHS Foundation Trust, United Kingdom.
Abstract
INTRODUCTION: Current PD assessment methods have inherent limitations. There is need for an objective method to assist clinical decisions and to facilitate evaluation of treatments. Accelerometers, and analysis using artificial neural networks (ANN), have shown potential as a method of motor symptom evaluation. This work describes the development of a novel PD disease state detection system informed by algorithms based on data collected in an unsupervised, home environment. We evaluated whether this approach can reproduce patient-completed symptom diaries and clinical assessment of disease state. METHODS: 34 participants with PD wore bilateral wrist-worn accelerometers for 4 h in a research facility (phase 1) and for 7 days at home whilst completing symptom diaries (phase 2). An ANN to predict disease state was developed based on home-derived accelerometer data. Using a leave-one-out approach, ANN performance was evaluated against patient-completed symptom diaries and against clinician rating of disease state. RESULTS: In the clinical setting, specificity for dyskinesia detection was extremely high (0.99); high specificity was also demonstrated for home-derived data (0.93), but with low sensitivity (0.38). In both settings, sensitivity for on/off detection was sub-optimal. ANN-derived values of the proportions of time in each disease state showed strong, significant correlations with patient-completed symptom diaries. CONCLUSION: Accurate, real-time evaluation of symptoms in an unsupervised, home environment, with this sensor system, is not yet achievable. In terms of the amounts of time spent in each disease state, ANN-derived results were comparable to those of symptom diaries, suggesting this method may provide a valuable outcome measure for medication trials.
INTRODUCTION: Current PD assessment methods have inherent limitations. There is need for an objective method to assist clinical decisions and to facilitate evaluation of treatments. Accelerometers, and analysis using artificial neural networks (ANN), have shown potential as a method of motor symptom evaluation. This work describes the development of a novel PD disease state detection system informed by algorithms based on data collected in an unsupervised, home environment. We evaluated whether this approach can reproduce patient-completed symptom diaries and clinical assessment of disease state. METHODS: 34 participants with PD wore bilateral wrist-worn accelerometers for 4 h in a research facility (phase 1) and for 7 days at home whilst completing symptom diaries (phase 2). An ANN to predict disease state was developed based on home-derived accelerometer data. Using a leave-one-out approach, ANN performance was evaluated against patient-completed symptom diaries and against clinician rating of disease state. RESULTS: In the clinical setting, specificity for dyskinesia detection was extremely high (0.99); high specificity was also demonstrated for home-derived data (0.93), but with low sensitivity (0.38). In both settings, sensitivity for on/off detection was sub-optimal. ANN-derived values of the proportions of time in each disease state showed strong, significant correlations with patient-completed symptom diaries. CONCLUSION: Accurate, real-time evaluation of symptoms in an unsupervised, home environment, with this sensor system, is not yet achievable. In terms of the amounts of time spent in each disease state, ANN-derived results were comparable to those of symptom diaries, suggesting this method may provide a valuable outcome measure for medication trials.
Authors: Martina Chirra; Luca Marsili; Linsdey Wattley; Leonard L Sokol; Elizabeth Keeling; Simona Maule; Gabriele Sobrero; Carlo Alberto Artusi; Alberto Romagnolo; Maurizio Zibetti; Leonardo Lopiano; Alberto J Espay; Ahmed Z Obeidat; Aristide Merola Journal: Telemed J E Health Date: 2018-08-23 Impact factor: 3.536
Authors: Joaquin A Vizcarra; Álvaro Sánchez-Ferro; Walter Maetzler; Luca Marsili; Lucia Zavala; Anthony E Lang; Pablo Martinez-Martin; Tiago A Mestre; Ralf Reilmann; Jeffrey M Hausdorff; E Ray Dorsey; Serene S Paul; Judith W Dexheimer; Benjamin D Wissel; Rebecca L M Fuller; Paolo Bonato; Ai Huey Tan; Bastiaan R Bloem; Catherine Kopil; Margaret Daeschler; Lauren Bataille; Galit Kleiner; Jesse M Cedarbaum; Jochen Klucken; Aristide Merola; Christopher G Goetz; Glenn T Stebbins; Alberto J Espay Journal: Mov Disord Date: 2019-03-22 Impact factor: 10.338
Authors: Eni Halilaj; Apoorva Rajagopal; Madalina Fiterau; Jennifer L Hicks; Trevor J Hastie; Scott L Delp Journal: J Biomech Date: 2018-09-13 Impact factor: 2.712
Authors: Kevin Moore; Emma O'Shea; Lorna Kenny; John Barton; Salvatore Tedesco; Marco Sica; Colum Crowe; Antti Alamäki; Joan Condell; Anna Nordström; Suzanne Timmons Journal: JMIR Mhealth Uhealth Date: 2021-06-03 Impact factor: 4.773
Authors: Mercedes Barrachina-Fernández; Ana María Maitín; Carmen Sánchez-Ávila; Juan Pablo Romero Journal: Sensors (Basel) Date: 2021-06-18 Impact factor: 3.576